177 related articles for article (PubMed ID: 37179357)
41. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
42.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
43. Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Roife D; Dai B; Kang Y; Perez MVR; Pratt M; Li X; Fleming JB
Clin Cancer Res; 2016 Dec; 22(24):6021-6030. PubMed ID: 27259561
[TBL] [Abstract][Full Text] [Related]
44. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
45. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
Guo P; Ma J; Li S; Guo Z; Adams AL; Gallo JM
Cancer Chemother Pharmacol; 2001 Aug; 48(2):169-76. PubMed ID: 11561783
[TBL] [Abstract][Full Text] [Related]
46. An integrated PK/PD model investigating the impact of tumor size and systemic safety on animal survival in SW1990 pancreatic cancer xenograft.
Yao QY; Zhou J; Yao Y; Xue JS; Guo YC; Jian WZ; Zhang RW; Qiu XY; Zhou TY
Acta Pharmacol Sin; 2023 Feb; 44(2):465-474. PubMed ID: 35953645
[TBL] [Abstract][Full Text] [Related]
47. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
48. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira.
Yu J; Drisko J; Chen Q
Oncol Rep; 2013 Jul; 30(1):149-56. PubMed ID: 23674070
[TBL] [Abstract][Full Text] [Related]
50. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.
N'Guessan KF; Davis HW; Chu Z; Vallabhapurapu SD; Lewis CS; Franco RS; Olowokure O; Ahmad SA; Yeh JJ; Bogdanov VY; Qi X
Mol Ther; 2020 Aug; 28(8):1876-1886. PubMed ID: 32516572
[TBL] [Abstract][Full Text] [Related]
51. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
52. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
53. A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Yamano T; Kubo S; Tomita N
Cancer Med; 2020 May; 9(10):3337-3343. PubMed ID: 32168428
[TBL] [Abstract][Full Text] [Related]
54. Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Iizuka K; Zhang C; Eshima K; Jin C; Eshima K; Fukushima M
Int J Oncol; 2018 Mar; 52(3):851-860. PubMed ID: 29344636
[TBL] [Abstract][Full Text] [Related]
55. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
[TBL] [Abstract][Full Text] [Related]
56. Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
Garcia-Cremades M; Pitou C; Iversen PW; Troconiz IF
AAPS J; 2019 Jan; 21(2):23. PubMed ID: 30706160
[TBL] [Abstract][Full Text] [Related]
57. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
58. Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Li YJ; Wu JY; Wang JM; Hu XB; Cai JX; Xiang DX
Acta Biomater; 2020 Jan; 101():519-530. PubMed ID: 31629893
[TBL] [Abstract][Full Text] [Related]
59. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract][Full Text] [Related]
60. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
